Arcutis Biotherapeutics, Inc. ARQT Proceeds from issuance of common stock and pre-funded warrants, net of issuance costs
Proceeds from issuance of common stock and pre-funded warrants, net of issuance costs at other companies
Other financials
Where this comes from
Reported directly by Arcutis Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept arqt:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts.
The official record: Arcutis Biotherapeutics, Inc.’s 10-K, filed February 25, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arcutis Biotherapeutics, Inc.'s proceeds from issuance of common stock and pre-funded warrants, net of issuance costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arcutis Biotherapeutics, Inc.'s proceeds from issuance of common stock and pre-funded warrants, net of issuance costs?
- Arcutis Biotherapeutics, Inc. (ARQT) reported proceeds from issuance of common stock and pre-funded warrants, net of issuance costs of $0 in Q4 2025.
- What does proceeds from issuance of common stock and pre-funded warrants, net of issuance costs mean?
- Captures the total cash inflows generated from the sale of common equity and pre-funded warrants to investors, net of any direct issuance costs. This metric indicates the company's ability to raise capital from public or private markets to fund operations, R&D, or strategic initiatives. It is a primary indicator of equity-based financing activity and potential shareholder dilution.